Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

Company Overview - Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative vaccines to combat infectious diseases [3] - The company has two commercial products: HEPLISAV-B® vaccine, approved in the U.S., EU, and UK for preventing hepatitis B virus infections in adults aged 18 and older, and CpG 1018® adjuvant, utilized in HEPLISAV-B and various adjuvanted COVID-19 vaccines [3] Upcoming Events - Dynavax will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on September 3rd at 4:30 p.m. ET [1] - Presentations from the conference will be available via webcast on the "Events & Presentations" page of the company's website [2]